Abstract
The effect of anastrozole ('Arimidex', ZD1033), a new, selective, non-steroidal aromatase inhibitor on in vivo aromatisation and plasma oestrogen levels was evaluated in post-menopausal women with breast cancer. Twelve patients progressing after treatment with tamoxifen were randomised to receive anastrozole 1 mg or 10 mg once daily for a 28 day period in a double-blinded crossover design. In vivo aromatisation and plasma oestrogen levels were determined before commencing treatment and at the end of each 4-week period. Treatment with anastrozole 1 and 10 mg reduced the percentage aromatisation from 2.25% to 0.074% and 0.043% (mean suppression of 96.7% and 98.1% from baseline) and suppressed plasma levels of oestrone, oestradiol and oestrone sulphate by > or = 86.5%, > or = 83.5% and > or = 93.5% respectively, irrespective of dose. Notably, several patients had their oestrone and oestradiol values suppressed beneath the sensitivity limit of the assays. In conclusion, anastrozole was found to be highly effective in inhibiting in vivo aromatisation with no difference in efficacy between the two drug doses. Contrary to previous studies on other aromatase inhibitors, this study revealed an internal consistency between the percentage aromatase inhibition and suppression of plasma oestrone sulphate.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Part of the work was presented at the Fourth Nottingham International Breast Cancer Conference, September 1995, at the ECCO 8 Conference in Paris, October 1995, and at the 18th Annual San Antonio Breast Cancer Symposium in December 1995
Rights and permissions
About this article
Cite this article
Geisler, J., King, N., Dowsett, M. et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 74, 1286–1291 (1996). https://doi.org/10.1038/bjc.1996.531
Issue Date:
DOI: https://doi.org/10.1038/bjc.1996.531
This article is cited by
-
Superior suppression of serum estrogens during neoadjuvant breast cancer treatment with letrozole compared to exemestane
Breast Cancer Research and Treatment (2024)
-
Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin
Breast Cancer Research and Treatment (2021)
-
Therapeutic Drug Monitoring of Oral Anti-Hormonal Drugs in Oncology
Clinical Pharmacokinetics (2019)
-
Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer
Breast Cancer Research and Treatment (2017)
-
Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients
Breast Cancer Research and Treatment (2017)